Einzeltreffer — DigiBib

To investigate the association between methotrexate (MTX) dosage and engraftment, graft-versus-host disease (GVHD) incidence, and survival in umbilical cord blood transplantation (UCBT), we compared transplant outcomes after UCBT with various GVHD prophylaxis regimens, using registry data with additional data collection. Patients transplanted for acute myeloid leukemia with a calcineurin inhibitor (CNI) and either MTX or mycophenolate mofetil (MMF) combination were selected. In total, 888 single-unit UCBTs (MTX 15-10-10 , 415; MTX 10-7-7 , 294; MTX 5-5-5 , 71; MMF, 108) were included. In multivariate analyses with MTX 15-10-10 as the reference, the likelihood of neutrophil and platelet engraftment was significantly worse in the MTX 10-7-7 group, and similarly better in MMF group compared with MTX 15-10-10 . All variables including CyA vs Tac and 4-group GVHD prophylaxis became significant for the risk of grade II-IV acute GVHD in the final multivariate model. We observed significant additional effects of combined MTX dose in the Tac group, which were larger with lower MTX dose and MMF. No significant difference was observed in survival risk among GVHD prophylaxis groups. Despite the potential background differences in the combined CNI and conditioning regimen, we conclude that the recommended GVHD prophylaxis is a combination of CyA plus MTX 15-10-10 or Tac plus MMF.

Titel:	Effect of methotrexate dose in graft-versus-host disease prophylaxis after single-unit cord blood transplantation in adult acute myeloid leukemia.
Autor/in / Beteiligte Person:	Terakura, S ; Kuwatsuka, Y ; Sugita, J ; Takahashi, S ; Ozawa, Y ; Ozeki, K ; Yoshioka, S ; Nakamae, H ; Kawakita, T ; Sawa, M ; Morishige, S ; Najima, Y ; Katsuoka, Y ; Sakaida, E ; Kouzai, Y ; Kimura, T ; Ichinohe, T ; Fukuda, T ; Atsuta, Y ; Murata, M ; Teshima, T
Link:	View record at Springer (Volltext)
Zeitschrift:	International journal of hematology, Jg. 113 (2021-06-01), Heft 6, S. 840-850
Veröffentlichung:	2008- : Tokyo : Springer Japan ; <i>Original Publication</i>: Amsterdam : Elsevier Science Publishers, c1991-, 2021
Medientyp:	academicJournal
ISSN:	1865-3774 (electronic)
DOI:	10.1007/s12185-021-03097-8
Schlagwort:	Adolescent Adult Allografts Dose-Response Relationship, Drug Female Humans Japan Male Middle Aged Retrospective Studies Cord Blood Stem Cell Transplantation Graft vs Host Disease prevention & control Leukemia, Myeloid, Acute therapy Methotrexate administration & dosage Registries
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Clinical Trial; Comparative Study; Journal Article Language: English [Int J Hematol] 2021 Jun; Vol. 113 (6), pp. 840-850. <i>Date of Electronic Publication: </i>2021 Feb 21. MeSH Terms: Cord Blood Stem Cell Transplantation* ; Registries* ; Graft vs Host Disease / prevention & control ; Leukemia, Myeloid, Acute / therapy ; Methotrexate / *administration & dosage ; Adolescent ; Adult ; Allografts ; Dose-Response Relationship, Drug ; Female ; Humans ; Japan ; Male ; Middle Aged ; Retrospective Studies References: Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 2004;351(22):2276–85. (PMID: 15564544) ; Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 2004;351(22):2265–75. (PMID: 15564543) ; Ooi J. Cord blood transplantation in adults. Bone Marrow Transplant. 2009;44(10):661–6. (PMID: 19802029) ; Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood. 2013;122(4):491–8. (PMID: 236738633952633) ; Takahashi S, Iseki T, Ooi J, Tomonari A, Takasugi K, Shimohakamada Y, et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood. 2004;104(12):3813–20. (PMID: 15280199) ; Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang MJ, Arcese W, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010;11(7):653–60. (PMID: 205581043163510) ; Sakai R, Taguri M, Oshima K, Mori T, Ago H, Adachi S, et al. A comparison of tacrolimus and cyclosporine combined with methotrexate for graft-versus-host disease prophylaxis, stratified by stem cell source: a retrospective nationwide survey. Int J Hematol. 2016;103(3):322–33. (PMID: 26800676) ; Terakura S, Atsuta Y, Tsukada N, Kobayashi T, Tanaka M, Kanda J, et al. Comparison of outcomes of 8/8 and 7/8 allele-matched unrelated bone marrow transplantation and single-unit cord blood transplantation in adults with acute leukemia. Biol Blood Marrow Transplant. 2016;22(2):330–8. (PMID: 26476205) ; Barker JN, Davies SM, DeFor T, Ramsay NK, Weisdorf DJ, Wagner JE. Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis. Blood. 2001;97(10):2957–61. (PMID: 11342417) ; Terakura S, Wake A, Inamoto Y, Murata M, Sakai R, Yamaguchi T, et al. Exploratory research for optimal GvHD prophylaxis after single unit CBT in adults: short-term methotrexate reduced the incidence of severe GvHD more than mycophenolate mofetil. Bone Marrow Transplant. 2017;52(3):423–30. (PMID: 27941766) ; Terakura S, Kuwatsuka Y, Yamasaki S, Wake A, Kanda J, Inamoto Y, et al. GvHD prophylaxis after single-unit reduced intensity conditioning cord blood transplantation in adults with acute leukemia. Bone Marrow Transplant. 2017;52(9):1261–7. (PMID: 28604665) ; Ogata M, Fukuda T, Teshima T. Human herpesvirus-6 encephalitis after allogeneic hematopoietic cell transplantation: what we do and do not know. Bone Marrow Transplant. 2015;50(8):1030–6. (PMID: 25915811) ; Martin PJ. The role of donor lymphoid cells in allogeneic marrow engraftment. Bone Marrow Transplant. 1990;6(5):283–9. (PMID: 2291990) ; Martin PJ. Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans. J Exp Med. 1993;178(2):703–12. (PMID: 8101864) ; Terakura S, Azuma E, Murata M, Kumamoto T, Hirayama M, Atsuta Y, et al. Hematopoietic engraftment in recipients of unrelated donor umbilical cord blood is affected by the CD34+ and CD8+ cell doses. Biol Blood Marrow Transplant. 2007;13(7):822–30. (PMID: 17580260) ; Vogelsang GB, Arai S. Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings. Bone Marrow Transplant. 2001;27(12):1255–62. (PMID: 11548843) ; Shiratori S, Ohigashi H, Takahashi S, Ara T, Goto H, Nakagawa M, et al. Reduced dose of MTX for GVHD prophylaxis promotes engraftment and decreases non-relapse mortality in umbilical cord blood transplantation. Ann Hematol. 2020;99(3):591–8. (PMID: 32006152) ; Yoshida S, Ohno Y, Nagafuji K, Yoshimoto G, Sugio T, Kamimura T, et al. Comparison of calcineurin inhibitors in combination with conventional methotrexate, reduced methotrexate, or mycophenolate mofetil for prophylaxis of graft-versus-host disease after umbilical cord blood transplantation. Ann Hematol. 2019;98(11):2579–91. (PMID: 31628517) ; Adachi Y, Ozeki K, Ukai S, Sagou K, Fukushima N, Kohno A. Optimal dosage of methotrexate for GVHD prophylaxis in umbilical cord blood transplantation. Int J Hematol. 2019;109(4):440–50. (PMID: 30680665) ; Fuji S, Tada Y, Nakata R, Nakata K, Koike M, Kida S, et al. GVHD prophylaxis by tacrolimus and mini-MTX in single-unit CBT: a single institute experience. Int J Hematol. 2020;111(2):278–83. (PMID: 31659626) ; Atsuta Y. Introduction of transplant registry unified management program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol. 2016;103(1):3–10. (PMID: 26547570) ; Atsuta Y, Suzuki R, Yoshimi A, Gondo H, Tanaka J, Hiraoka A, et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int J Hematol. 2007;86(3):269–74. (PMID: 17988995) ; Kanda J. Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation. Int J Hematol. 2016;103(1):11–9. (PMID: 26588927) ; Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628–33. (PMID: 198960872861656) ; Schoemans H, Theunissen K, Maertens J, Boogaerts M, Verfaillie C, Wagner J. Adult umbilical cord blood transplantation: a comprehensive review. Bone Marrow Transplant. 2006;38(2):83–93. (PMID: 16751788) ; Przepiorka D, Weisdorf D, Martin P, Klingemann H, Beatty P, Hows J, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825–8. (PMID: 7581076) ; Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9(4):215–33. (PMID: 12720215) ; Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81. ; Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695–706. (PMID: 10204198) ; Cox DR. Regression models and life-tables. J Roy Stat Soc Ser B (Methodol). 1972;34(2):187–220. ; Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509. ; Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8. (PMID: 23208313) ; Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the disease risk index for allogeneic stem cell transplantation. Blood. 2014;123(23):3664–71. (PMID: 247442694047501) ; Arai Y, Takeda J, Aoki K, Kondo T, Takahashi S, Onishi Y, et al. Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy. Blood. 2015;126(3):415–22. (PMID: 260319164504951) ; Kanda J, Morishima Y, Terakura S, Wake A, Uchida N, Takahashi S, et al. Impact of graft-versus-host disease on outcomes after unrelated cord blood transplantation. Leukemia. 2016. ; Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75(3):555–62. (PMID: 2297567) ; Storb R, Gyurkocza B, Storer BE, Sorror ML, Blume K, Niederwieser D, et al. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2013;31(12):1530–8. (PMID: 23478054) ; Isobe M, Konuma T, Kato S, Tanoue S, Mizusawa M, Oiwa-Monna M, et al. Development of pre-engraftment syndrome, but not acute graft-versus-host disease, reduces relapse rate of acute myelogenous leukemia after single cord blood transplantation. Biol Blood Marrow Transplant. 2019;25(6):1187–96. (PMID: 30771495) ; Kanda J, Kaynar L, Kanda Y, Prasad VK, Parikh SH, Lan L, et al. Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment. Bone Marrow Transplant. 2013;48(7):926–31. (PMID: 233342743701735) ; Uchida N, Wake A, Nakano N, Ishiwata K, Takagi S, Tsuji M, et al. Mycophenolate and tacrolimus for graft-versus-host disease prophylaxis for elderly after cord blood transplantation: a matched pair comparison with tacrolimus alone. Transplantation. 2011;92(3):366–71. (PMID: 21677598) ; Konuma T, Kanda J, Inamoto Y, Hayashi H, Kobayashi S, Uchida N, et al. Improvement of early mortality in single-unit cord blood transplantation for Japanese adults from 1998 to 2017. Am J Hematol. 2019;2:2. ; Konuma T, Ooi J, Uchida N, Ogawa H, Ohashi K, Kanamori H, et al. Granulocyte colony-stimulating factor combined regimen in cord blood transplantation for acute myeloid leukemia: a nationwide retrospective analysis in Japan. Haematologica. 2014;99(12):e264–8. (PMID: 252166864258742) Grant Information: 18k08351 Japan Society for the Promotion of Science Contributed Indexing: Keywords: GVHD prophylaxis; Graft-versus-host disease (GVHD); Immunosuppressant selection; Methotrexate dose; Single-unit umbilical cord blood transplantation Substance Nomenclature: YL5FZ2Y5U1 (Methotrexate) Entry Date(s): Date Created: 20210221 Date Completed: 20210531 Latest Revision: 20210531 Update Code: 20231215

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Achtung:

Effect of methotrexate dose in graft-versus-host disease prophylaxis after single-unit cord blood transplantation in adult acute myeloid leukemia.